Pharmafile Logo
Pharmafocus logo
Advanced Search

evolocumab

Showing 8 posts of 8 posts found.

Amgen earns first Japanese nod for PCSK9 inhibitor

January 25, 2016
Sales and Marketing Amgen, Astellas, Japan, PCSK9 inhibitor, Repatha, evolocumab, high cholesterol

The Japanese Ministry of Health, Labour and Welfare has approved Amgen’s cholesterol-lowering medication Repatha, in a joint venture between Amgen …

News

NICE rejects Amgen’s Repatha in draft guidance

November 18, 2015
Research and Development, Sales and Marketing Amgen, NICE, Repatha, evolocumab, high cholesterol

NICE has published draft guidance rejecting Amgen’s Repatha as a treatment for people with high cholesterol.   

News

FDA approves Amgen’s cholesterol lowering drug

August 28, 2015
Medical Communications, Research and Development Amgen, FDA, Repatha, evolocumab

The FDA has endorsed Amgen’s cholesterol-lowering medication, Repatha, for the use in patients with high cholesterol. It follows Amgen’s successful …

News
ESC congress sign

NHS looks to ESC for next-gen heart drug data

August 28, 2015
Medical Communications, Research and Development ALN-PCScs, Repatha, alirocumab, cardiology, cardiovascular disease, cvd, evolocumab, heart disease, high cholesterol, praluent

New data is expected to be presented at the European Cardiology Society congress in London, on the high cholesterol drugs …

News

Amgen’s Repatha wins PCSK9 heart drug race

July 21, 2015
Sales and Marketing Amgen, European Commission, PCKS9, Repatha, evolocumab, high cholesterol

The European Commission has signed off on Amgen’s Repatha, making it the first in a new class of cholesterol-lowering drugs …

News
Sanofi image

Sanofi and Amgen cholesterol drugs shine

March 16, 2015
Sales and Marketing Amgen, PCSK9, Repatha, Sanofi, alirocumab, evolocumab, praluent

Two large Phase III studies of Sanofi’s Praluent and Amgen’s Repatha have found the biologic cholesterol-lowering drugs are more effective …

News
Sanofi image

Sanofi showcases alirocumab at AHA

November 20, 2014
Sales and Marketing Amgen, PCSK9, Regeneron, Sanofi, aha, alirocumab, evolocumab

Sanofi and Regeneron released a battery of new Phase III data on their PCSK9 inhibitor alirocumab this week, reinforcing the …

News
Amgen image

Success for Amgen’s ‘bad’ cholesterol injection

March 18, 2014
Research and Development, Sales and Marketing Amgen, LDL, PCSK9, evolocumab, hofh, tesla

An investigational PCSK9 Inhibitor from Amgen has reduced LDL-C (‘bad’ cholesterol) in patients suffering from a rare genetic disorder in …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024